var data={"title":"Liposomal amphotericin B: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Liposomal amphotericin B: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5636?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=liposomal-amphotericin-b-patient-drug-information\" class=\"drug drug_patient\">see &quot;Liposomal amphotericin B: Patient drug information&quot;</a> and <a href=\"topic.htm?path=liposomal-amphotericin-b-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Liposomal amphotericin B: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24673687\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>AmBisome</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134882\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>AmBisome</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134901\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antifungal Agent, Parenteral</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134884\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Lipid-based amphotericin formulations (AmBisome) may be confused with conventional formulations (desoxycholate [Amphocin, Fungizone]) or with other lipid-based amphotericin formulations (amphotericin B lipid complex [Abelcet], amphotericin B cholesteryl sulfate complex [Amphotec]). Lipid-based and conventional formulations are <b>not </b>interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Usual dosage range:</b> IV: 3 to 6 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Premedication: For patients who experience nonanaphylactic immediate infusion-related reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: A nonsteroidal anti-inflammatory agent &plusmn; diphenhydramine; <b>or</b> acetaminophen with diphenhydramine; <b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Indication-specific dosing:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Aspergillus</b> <b>(systemic infection) (alternative therapy) (off-label dose):</b> 3 to 5 mg/kg/day; minimum duration of treatment is 6 to 12 weeks and depends on site of infection, extent of disease and level/duration of immunosuppression (IDSA [Patterson 2016]). <b>Note:</b> Guidelines recommend amphotericin B lipid formulations be considered for invasive aspergillosis only when triazoles, specifically voriconazole, are contraindicated or not tolerated (IDSA [Patterson 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Aspergillosis, empiric therapy (off-label dose): </b>3 mg/kg/day. <b>Note:</b> Guidelines recommend amphotericin B lipid formulations be considered for invasive aspergillosis only when triazoles, specifically voriconazole, are contraindicated or not tolerated (IDSA [Patterson 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Empiric therapy: </i>3 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Invasive infection:</i> 3 to 5 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendations (IDSA [Pappas 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Candidemia (non-neutropenic patients): </i>3 to 5 mg/kg/day; may transition to fluconazole (usually after 5 to 7 days) in clinically stable patients, with fluconazole-susceptible isolates and negative repeat cultures. Total duration of antifungal therapy is at least 2 weeks <i>after</i> the documented clearance of <i>Candida</i> from the bloodstream and resolution of candidemia-associated symptoms in patients without metastatic complications. <b>Note: </b>An amphotericin B lipid formation is considered a reasonable alternative agent if there is intolerance, limited availability, or resistance to other antifungals. In patients with suspected azole- and echinocandin-resistant infections, an amphotericin B lipid formulation is preferred.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Candidemia (neutropenic patients): </i>3 to 5 mg/kg/day; may transition to fluconazole during persistent neutropenia in clinically stable patients, with fluconazole-susceptible isolates and negative repeat cultures. Total duration of antifungal therapy is at least 2 weeks <i>after</i> the documented clearance of <i>Candida</i> from the bloodstream and resolution of neutropenia and candidemia-associated symptoms in patients without metastatic complications. <b>Note:</b> An amphotericin B lipid formation is considered a potential alternative agent, but less attractive option due to its potential for toxicity. However, for infections due to <i>C. krusei</i>, an amphotericin B lipid formulation is a preferred agent.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Central nervous system (eg, meningitis):</i> 5 mg/kg/day (with or without oral flucytosine); step-down to fluconazole therapy is recommended after initial response to treatment</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Chronic disseminated (hepatosplenic)</i>: 3 to 5 mg/kg/day; after several weeks, transition to oral fluconazole in clinically stable, fluconazole-susceptible patients</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Empiric therapy, suspected<i> invasive candidiasis </i> (non-neutropenic ICU patients) (off-label use):</i> 3 to 5 mg/kg/day; treatment should continue for 14 days in patients with clinical improvement. Consider discontinuing after 4 to 5 days in patients with no clinical response. <b>Note: </b>considered an alternative to echinocandins.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Endocarditis (native or prosthetic valve) or infected implantable cardiac devices (eg, pacemaker, ICD, VAD):</i> 3 to 5 mg/kg/day (with or without flucytosine); for native or prosthetic valve endocarditis, therapy should continue for at least 6 weeks after valve replacement surgery (longer durations in patients with abscesses or other complications); for patients with implantable cardiac devices, therapy should continue for 4 to 6 weeks after surgery (4 for infections limited to generator pockets and at least 6 weeks for infections involving the wires). <b>Note:</b> May transition to fluconazole if patient clinically stable with fluconazole-susceptible isolates in whom <i>Candida</i> has cleared from the bloodstream; chronic or long-term suppression with fluconazole may be required (eg, prosthetic valve, valve-replacement not possible).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Endophthalmitis (with or without vitritis): </i>Fluconazole- or voriconazole-resistant isolates: 3 to 5 mg/kg/day (with or without flucytosine) for at least 4 to 6 weeks until examination indicates resolution; for patients with vitritis or with macular involvement (with or without vitritis), an intravitreal injection of voriconazole or amphotericin B deoxycholate is also recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Intra-abdominal candidiasis: </i>3 to 5 mg/kg/day; duration of therapy determined by clinical response and source control</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Osteomyelitis or septic arthritis due to Candida (alternative therapy):</i> 3 to 5 mg/kg/day for at least 2 weeks, followed by fluconazole</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Coccidioidomycosis in HIV-infected patients (off-label use):</b> <i>Non-CNS infection, severe (ie, diffuse pulmonary or severely ill with extrathoracic, disseminated disease): </i>3 to 5 mg/kg/day until clinical improvement, then initiate triazole therapy (eg, fluconazole or itraconazole) (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cryptococcosis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Disseminated cryptococcosis (non-CNS or severe pulmonary disease) in HIV-infected patients: </i>IV: 3 to 4 mg/kg/day with flucytosine (preferred) or fluconazole, or without a concomitant agent (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Meningitis in HIV-infected patients:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Manufacturer&rsquo;s labeling: 6 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate recommendations: 3 to 4 mg/kg/day with flucytosine (preferred) or fluconazole, or without a concomitant agent (HHS [OI adult 2017]); doses up to 6 mg/kg/dose have been reported for treatment of meningoencephalitis and may be considered for treatment failure or high fungal burden disease (IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Fungal sinusitis:</b> Limited data in immunocompromised patients have shown efficacy with 3 to 10 mg/kg/day (Barron 2005; Pagano 2004; Rokicka 2006). <b>Note:</b> An azole antifungal is recommended if causative organism is <i>Aspergillus</i> spp or <i>Pseudallescheria boydii</i> (<i>Scedosporium</i> sp).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Histoplasmosis treatment in HIV-infected patients (off-label use; HHS [OI adult 2017]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Disseminated disease, moderately severe to severe:</i> Induction therapy: 3 mg/kg/day for at least 2 weeks, followed by oral itraconazole for maintenance therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Histoplasma meningitis</i>: Induction therapy: 5 mg/kg/day for 4 to 6 weeks, followed by oral itraconazole for maintenance therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leishmaniasis (cutaneous) in HIV-infected patients (off-label use):</b> 2 to 4 mg/kg/day for 10 days or an interrupted schedule (eg, 4 mg/kg on days 1 through 5, and then on days 10, 17, 24, 31, 38). Total dose administered should be 20 to 60 mg/kg (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leishmaniasis (visceral):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunocompetent: 3 mg/kg/day on days 1 through 5, and 3 mg/kg/day on days 14 and 21; a repeat course may be given in patients who do not achieve parasitic clearance</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immunocompromised: 4 mg/kg/day on days 1 through 5, and 4 mg/kg/day on days 10, 17, 24, 31, and 38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leishmaniasis (visceral) in HIV-infected patients (off-label use; HHS [OI adult 2017]):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: 2 to 4 mg/kg/day <b>or</b> an interrupted schedule (eg, 4 mg/kg on days 1 through 5, and then on days 10, 17, 24, 31, and 38). Total dose administered: 20 to 60 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic maintenance therapy (for patients with a CD4 count &lt;200 cells/mm<sup>3</sup>): 4 mg/kg every 2 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningitis (secondary to contaminated [eg, <i>Exserohilum rostratum]</i> steroid products), severe or in patients not improving with voriconazole monotherapy (off-label use) (CDC 2013; Kauffman 2012):</b> IV: 5 to 6 mg/kg/day in combination with voriconazole for &ge;3 months; a higher dose (7.5 mg/kg/day) may be considered in patients who are not improving. <b>Note:</b> Consult an infectious disease specialist and current CDC guidelines for specific treatment recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteoarticular infection (secondary to contaminated [eg,</b> <b><i>Exserohilum rostratum</i></b><b>] steroid products), severe or in patients with clinical instability (off-label use) (CDC 2013; Kauffman 2012):</b> IV: 5 mg/kg/day in combination with voriconazole for &ge;3 months. <b>Note: </b>Consult an infectious disease specialist and current CDC guidelines for specific treatment recommendations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Talaromyces marneffei</i></b> <b>infection in HIV-infected patients (off-label use):</b> 3 to 5 mg/kg/day for 2 weeks, followed by oral itraconazole for 10 weeks, followed by chronic maintenance therapy (HHS [OI adult 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134894\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=liposomal-amphotericin-b-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Liposomal amphotericin B: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Lipid-based amphotericin formulations (AmBisome) may be confused with conventional formulations (desoxycholate [Amphocin, Fungizone]) or with other lipid-based amphotericin formulations (amphotericin B lipid complex [Abelcet], amphotericin B cholesteryl sulfate complex [Amphotec]). Lipid-based and conventional formulations are <b>not </b>interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Empiric therapy: Infants, Children, and Adolescents: IV: 3 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment, susceptible systemic infection: Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> <b>Premedication:</b> For patients who experience nonanaphylactic immediate infusion-related reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: A nonsteroidal anti-inflammatory agent &plusmn; diphenhydramine; <b>or</b> acetaminophen with diphenhydramine; <b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Aspergillus, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Invasive: </i>Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily (IDSA [Patterson 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Endocarditis:</i> Children and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Blastomycosis, invasive:</b> Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily for initial therapy; if CNS infection 4 to 6 weeks may be needed; followed by oral itraconazole for a total of 12 months (IDSA [Chapman 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Candidiasis,</b> <b>treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CNS infection: </i>Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily with or without flucytosine (IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Endocarditis:</i> Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015]; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Invasive (independent of HIV status):</i> Infants, Children, Adolescents: 3 to 5 mg/kg/dose once daily (Filioti 2007; IDSA [Pappas 2016]); <b>Note:</b> In HIV-exposed/-positive patients (off-label use), doses at the higher end of the range may be considered (5 mg/kg/day) (HHS [OI pediatric 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Coccidioidomycosis, invasive:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-exposed/-positive: <i>Non-CNS infection, severe (ie, diffuse pulmonary or severely ill with extrathoracic, disseminated disease) (off-label use)</i><i>:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: IV: 5 mg/kg/dose once daily until clinical improvement (minimum of several weeks of therapy), then initiate triazole therapy (eg, fluconazole or itraconazole); dose may be increased to as high as 10 mg/kg/dose once daily for life-threatening infection (HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: IV: 3 to 5 mg/kg/dose once daily until clinical improvement, then switch to fluconazole or itraconazole (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HIV-exposed/-positive:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Disseminated infection, nonpulmonary:</i> Infants, Children, and Adolescents: IV: 2 to 5 mg/kg/dose once daily with or without concomitant azole antifungal (IDSA [Galgiani 2005])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Pulmonary infection, diffuse: </i>Infants, Children, and Adolescents: IV: 2 to 5 mg/kg/dose once daily for several weeks, followed by an oral azole antifungal for a total length of therapy &ge;12 months (IDSA [Galgiani 2005])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cryptococcosis, invasive:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dissemin</i>\n      <i>ated cryptococcosis (non-CNS or severe pulmonary disease) (off-label use):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children (independent of HIV status): IV: 3 to 5 mg/kg/dose once daily with oral flucytosine; if flucytosine unavailable or not tolerated, may administer alone or in combination with high-dose fluconazole in HIV-exposed/-positive patients (HHS [OI pediatric 2016]; IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Non-HIV-exposed/-positive: IV: 3 to 4 mg/kg/dose once daily for at least 14 days; may consider addition of oral flucytosine (IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">HIV-exposed/-positive: IV: 3 to 4 mg/kg/dose once daily with or without flucytosine or fluconazole (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Meningitis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Non-HIV-exposed/-positive (off-label use):</i> Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily with flucytosine (IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>HIV-exposed/-positive:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Manufacturer&rsquo;s labeling: Infants, Children, and Adolescents: IV: 6 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Alternate dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Infants and Children: IV: 6 mg/kg/dose once daily with or without oral flucytosine or high dose fluconazole for a minimum 2-week induction; <b>Note:</b> Minimum 2-week induction, followed by consolidation and chronic suppressive therapy; a longer duration of induction therapy may be necessary if CSF is not negative or lack of clinical improvement (HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Adolescents: IV: 3 to 4 mg/kg/dose once daily with or without oral flucytosine or fluconazole (HHS [OI adult 2017]); doses up to 6 mg/kg/dose have been reported for treatment of meningoencephalitis and may be considered for treatment failure or high fungal burden disease (IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Histoplasmosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-exposed/-positive (off-label use):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Disseminated infection (non-CNS disease):</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Infants and Children: IV: 3 to 5 mg/kg/dose once daily for at least 2 weeks for induction; if itraconazole not tolerated for consolidation therapy, may continue for 4 to 6 weeks (HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Adolescents: IV: 3 mg/kg/dose once daily for at least 2 weeks for induction (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>CNS disease:</i> Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily for 4 to 6 weeks for induction, followed by consolidation therapy (HHS [OI adult 2017]; HHS [OI pediatric 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HIV-exposed/-positive: <i>Acute pulmonary disease or disseminated (non-CNS):</i> Infants, Children, and Adolescents: IV: 3 mg/kg/dose once daily for 1 to 2 weeks followed by oral itraconazole for a total of 12 weeks; conventional amphotericin B typically preferred (IDSA [Wheat 2007])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leishmaniasis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cutaneous infection, treatment in HIV-infected patients (off-label use):</i> Adolescents: 2 to 4 mg/kg/dose once daily for 10 days or an interrupted schedule of 4 mg/kg/dose on days 1 to 5, and on days 10, 17, 24, 31, and 38 to achieve a <b>total</b> <b>dose</b> of 20 to 60 mg/kg (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Visceral infection, treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Immunocompetent:</i> Infants, Children, and Adolescents: IV: Initial: 3 mg/kg/dose once daily on days 1 to 5, and 3 mg/kg/dose on days 14 and 21; a repeat course may be given in patients who do not achieve parasitic clearance</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Immunocompromised:</i> Infants, Children, and Adolescents: 4 mg/kg/dose once daily on days 1 to 5, and 4 mg/kg/day on days 10, 17, 24, 31, and 38</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>HIV-infected patients (off-label use):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Treatment: Adolescents: IV: 2 to 4 mg/kg/dose once daily or an interrupted schedule of 4 mg/kg/dose on days 1 to 5, and on days 10, 17, 24, 31, and 38 to achieve a <b>total</b> <b>dose</b> of 20 to 60 mg/kg (HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Chronic maintenance therapy: Adolescents: IV: 4 mg/kg/dose every 2 to 4 weeks; <b>Note:</b> Use reserved for patients with visceral infection and CD4 count &lt;200 cells/mm<sup>3 </sup>(HHS [OI adult 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Talaromyces marneffei</i></b> <b>infection in HIV-infected patients (off-label use):</b> Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134885\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134886\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; has been successfully administered to patients with preexisting renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">End-stage renal disease (ESRD) on intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Poorly dialyzed; no dosage adjustment necessary (Heintz 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CVVH/CVVHD/CVVHDF: No dosage adjustment necessary (Heintz 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22902761\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24673688\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AmBisome: 50 mg (1 ea) [contains cholesterol, distearoyl phosphatidylglycerol, hydrogenated soy phosphatidylcholine, sodium succinate hexahydrate, sucrose, tocopherol, dl-alpha]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134852\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134869\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer via intravenous infusion, over a period of approximately 2 hours. Infusion time may be reduced to approximately 1 hour in patients in whom the treatment is well-tolerated. If the patient experiences discomfort during infusion, the duration of infusion may be increased. Existing intravenous line should be flushed with D<sub>5</sub>W before and after infusion (if not feasible, administer through a separate line). An in-line membrane filter (not less than 1 micron) may be used.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">For a patient who experiences chills, fever, hypotension, nausea, or other nonanaphylactic immediate infusion-related reactions, premedicate with the following drugs, 30 to 60 minutes prior to drug administration: A nonsteroidal (eg, ibuprofen, choline magnesium trisalicylate) &plusmn; diphenhydramine <b>or </b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134868\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cryptococcal meningitis in HIV-infected patients:</b>  Treatment of cryptococcal meningitis in HIV-infected patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fungal infections, empiric therapy: </b> Empiric treatment in febrile neutropenic patients with presumed fungal infection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fungal infections, systemic therapy:</b>  Treatment of systemic infections caused by <i>Aspergillus</i> sp, <i>Candida</i> sp, and/or <i>Cryptococcus</i> sp in patients refractory to conventional amphotericin B deoxycholate therapy or when renal impairment or unacceptable toxicity precludes the use of the deoxycholate formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leishmaniasis (visceral):</b>  Treatment of visceral leishmaniasis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475063\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Candidiasis (invasive) in HIV-exposed/-infected patients (infants and children); Candidiasis, empiric therapy (non-neutropenic ICU patients); Coccidioidomycosis in HIV-exposed/-infected patients (infants and children); Coccidioidomycosis in HIV-infected patients (adolescents and adults); Cryptococcosis, disseminated (non-CNS) in HIV-exposed/-infected patients (infants and children); Fungal meningitis (secondary to contaminated [eg, Exserohilum rostratum] steroid products); Fungal osteoarticular infections (secondary to contaminated [eg, Exserohilum rostratum] steroid products); Histoplasmosis in HIV-exposed/-infected patients (infants and children); Histoplasmosis in HIV-infected patients (adolescents and adults); Leishmaniasis (cutaneous) in HIV-infected patients (adolescents and adults); Leishmaniasis (visceral) in HIV-infected patients (adolescents and adults); Talaromyces marneffei infection in HIV-infected patients (adolescents and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134910\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:2em;\">AmBisome may be confused with Ambisolm, Ambisom</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Lipid-based amphotericin formulations (AmBisome) may be confused with conventional formulations (Amphocin, Fungizone) or with other lipid-based amphotericin formulations (Abelcet, Amphotec)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of conventional amphotericin formulation never exceed 1.5 mg/kg.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134859\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Percentage of adverse reactions is dependent upon population studied and may vary with respect to premedications and underlying illness. Incidence of decreased renal function and infusion-related events are lower than rates observed with amphotericin B deoxycholate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (8% to 20%), tachycardia (9% to 19%), peripheral edema (15%), edema (12% to 14%), hypotension (7% to 14%), chest pain (8% to 12%), localized phlebitis (9% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills (29% to 48%), insomnia (17% to 22%), headache (9% to 20%), pain (14%), anxiety (7% to 14%), confusion (9% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (5% to 25%), pruritus (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia (31% to 51%), hypomagnesemia (15% to 50%), hyperglycemia (8% to 23%), hypocalcemia (5% to 18%), hyponatremia (9% to 12%), hypervolemia (8% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (16% to 40%), vomiting (11% to 32%), diarrhea (11% to 30%), abdominal pain (7% to 20%), constipation (15%), anorexia (10% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Nephrotoxicity (14% to 47%), hematuria (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (27% to 48%), leukopenia (15% to 17%), thrombocytopenia (6% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase (7% to 22%), hyperbilirubinemia (&le;18%), increased serum ALT (15%), increased serum AST (13%), abnormal hepatic function tests (not specified) (4% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Transfusion reaction (9% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Sepsis (7% to 14%), infection (11% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (6% to 13%), back pain (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased serum creatinine (18% to 40%), increased blood urea nitrogen (7% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (18% to 23%), pulmonary disease (14% to 18%), cough (2% to 18%), epistaxis (9% to 15%), pleural effusion (13%), rhinitis (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Infusion related reactions (4% to 21%; fever [7% to 24%], chills [6% to 24%], vomiting [4% to 16%], nausea [8% to 14%], dyspnea [5% to 10%], tachycardia [2% to 10%], hypertension [2% to 9%], vasodilation [5%], hypotension [4%], hyperventilation [1%], hypoxia [&le;1%])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">2% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Atrial fibrillation, bradycardia, cardiac arrest, cardiac arrhythmia, cardiomegaly, facial edema, flushing, heart valve disease, orthostatic hypotension, vascular disorder, vasodilatation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (7% to 9%), abnormality in thinking, agitation, coma, depression, drowsiness, dysesthesia, dystonia, hallucination, malaise, nervousness, paresthesia, rigors, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (7%), alopecia, cellulitis, dermal ulcer, dermatological reaction, maculopapular rash, skin discoloration, urticaria, vesiculobullous dermatitis, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypernatremia (4%), acidosis, hyperchloremia, hyperkalemia, hypermagnesemia, hyperphosphatemia, hypophosphatemia, increased lactate dehydrogenase, increased nonprotein nitrogen</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal hemorrhage (10%), aphthous stomatitis, dyspepsia, dysphagia, enlargement of abdomen, eructation, fecal incontinence, flatulence, gingival hemorrhage, hematemesis, hemorrhoids, hiccups, increased serum amylase, intestinal obstruction, mucositis, rectal disease, stomatitis, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Dysuria, toxic nephrosis, urinary incontence, vaginal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Blood coagulation disorder, bruise, decreased prothrombin time, hemophthalmos, hemorrhage, hypoproteinemia, increased prothrombin time, oral hemorrhage, petechia, purpura</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatic injury, hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), hepatomegaly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Delayed hypersensitivity, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Graft versus host disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Herpes simplex infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Inflammation at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia, neck pain, ostealgia, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis, dry eyes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Acute renal failure, renal failure, renal function abnormality</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Hypoxia (6% to 8%), asthma, atelectasis, dry nose, flu-like symptoms, hemoptysis, hyperventilation, pharyngitis, pneumonia, pulmonary edema, respiratory alkalosis, respiratory failure, respiratory insufficiency, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Procedural complication (8% to 10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and/or case reports: Agranulocytosis, angioedema, bronchospasm, cyanosis, erythema, hemorrhagic cystitis, hypoventilation, rhabdomyolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134872\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to amphotericin B deoxycholate or any component of the formulation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134856\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis: Has been reported with amphotericin B-containing drugs; facilities for cardiopulmonary resuscitation should be available during administration due to the possibility of anaphylactic reaction. If a severe anaphylactic reaction occurs, the infusion should be immediately discontinued; the patient should not receive further infusions. Administer under close clinical observation during initial dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Acute reactions (including fever and chills) may occur 1 to 3 hours after starting infusions; reactions are more common with the first few doses and generally diminish with subsequent doses. Immediately discontinue infusion if a severe anaphylactic reaction occurs; the patient should not receive further infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: In a scientific statement from the American Heart Association, amphotericin has been determined to be an agent that may cause direct myocardial toxicity (magnitude: moderate/major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Leukocyte transfusions: Acute pulmonary toxicity has been reported in patients receiving simultaneous leukocyte transfusions and amphotericin B.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298746\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134861\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9499&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May diminish the therapeutic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Amphotericin B may enhance the adverse/toxic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May increase the serum concentration of Amphotericin B. Specifically, dronabinol may displace amphotericin B from its protein-binding sites, leading to an increased concentration of active, unbound drug.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Stibogluconate: Amphotericin B may enhance the cardiotoxic effect of Sodium Stibogluconate. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134863\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6866584\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Amphotericin crosses the placenta and enters the fetal circulation. Amphotericin B is recommended for the treatment of serious systemic fungal diseases in pregnant women; refer to current guidelines (IDSA [Pappas 2016]; King 1998; Pilmus 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6866586\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if amphotericin is excreted into breast milk. Due to its poor oral absorption, systemic exposure to the nursing infant is expected to be decreased; however, because of the potential for toxicity, breast-feeding is not recommended by the manufacturer (Mactal-Haaf 2001).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14637213\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">If on parenteral nutrition, may need to adjust the amount of lipid infused. The lipid portion of amphotericin B (liposomal) formulation contains 0.27 kcal per 5 mg (Sacks 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134865\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Renal function (monitor frequently during therapy), electrolytes (especially potassium and magnesium), liver function tests, temperature, hematocrit, PT/PTT, CBC; monitor input and output; monitor for signs of hypokalemia (muscle weakness, cramping, drowsiness, ECG changes, etc); monitor cardiac function if used concurrently with corticosteroids</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134855\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death. Proposed mechanism suggests that amphotericin causes an oxidation-dependent stimulation of macrophages (Lyman 1992).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134871\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Exhibits nonlinear kinetics (greater than proportional increase in serum concentration with an increase in dose) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 0.1 to 0.16 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 7 to 10 hours (following a single 24-hour dosing interval); Terminal half to life: 100 to 153 hours (following multiple dosing up to 49 days)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322989\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (AmBisome Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $272.08</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038526\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>AmBisome (AE, AR, AT, AU, BE, CH, CY, DE, DK, ES, ET, FI, FR, GB, GR, HK, HN, IE, IL, IT, JP, KR, KW, LB, LU, LV, MT, NL, NO, PL, PT, PY, QA, RU, SA, SE, SG, TH, TR, TW);</li>\n      <li>Ambisome (BB, BR, HU, IS, SI);</li>\n      <li>Amfostat (MX);</li>\n      <li>Amphotec (CN);</li>\n      <li>Fengkesong (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    AmBisome (amphotericin B [liposomal]) [prescribing information]. San Dimas, CA: Gilead Sciences, Inc; May 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barron MA, Lay M, Madinger NE, &ldquo;Surgery and Treatment with High-Dose Liposomal Amphotericin B for Eradication of Craniofacial Zygomycosis in a Patient with Hodgkin&rsquo;s Disease Who Had Undergone Allogeneic Hematopoietic Stem Cell Transplantation,&rdquo; <i>J Clin Microbiol</i>, 2005, 43(4):2012-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/15815047/pubmed\" target=\"_blank\" id=\"15815047\">15815047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &ldquo;Interim Treatment Guidance for Central Nervous System (CNS) and Parameningeal Infections Associated With Injection of Contaminated Steroid Products,&rdquo; October 23, 2013. Available at <a href=\"http://www.cdc.gov/hai/outbreaks/clinicians/index.html\" target=\"_blank\">http://www.cdc.gov/hai/outbreaks/clinicians/index.html</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapman SW, Dismukes WE, Proia LA, et al, &quot;Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2008, 46(12):1801-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/18462107/pubmed\" target=\"_blank\" id=\"18462107\">18462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edwards JE Jr, Bodey GP, Bowden RA, et al, &ldquo;International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections,&rdquo; <i>Clin Infect Dis</i>, 1997, 25(1):43-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/9243032/pubmed\" target=\"_blank\" id=\"9243032\">9243032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eggimann P, Francioli P, Bille J, et al, &ldquo;Fluconazole Prophylaxis Prevents Intra-abdominal Candidiasis in High-Risk Surgical Patients,&rdquo; <i>Crit Care Med</i>, 1999, 27(6):1066-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/10397206/pubmed\" target=\"_blank\" id=\"10397206\">10397206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Emminger W, Graninger W, Emminger-Schmidmeir W, et al, &ldquo;Tolerance of High Doses of Amphotericin B by Infusion of a Liposomal Formulation in Children With Cancer,&rdquo; <i>Ann Hematol</i>, 1994, 68:27-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/8110875/pubmed\" target=\"_blank\" id=\"8110875\">8110875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fichtenbaum CJ, Zackin R, Rajicic N, et al, &ldquo;Amphotericin B Oral Suspension for Fluconazole-Refractory Oral Candidiasis in Persons With HIV Infection. Adult AIDS Clinical Trials Group Study Team 295,&rdquo; <i>AIDS</i>, 2000, 14(7):845-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/10839593/pubmed\" target=\"_blank\" id=\"10839593\">10839593</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Filioti J, Spiroglou K, Panteliadis CP, Roilides E. Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. <i>Intensive Care Med</i>. 2007;33(7):1272-1283. doi: 10.1007/s00134-007-0672-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/17503015/pubmed\" target=\"_blank\" id=\"17503015\">17503015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galgiani JN, Ampel NM, Blair JE, et al; Infectious Diseases Society of America. Coccidioidomycosis. <i>Clin Infect Dis</i>. 2005;41(9):1217-1223. doi: 10.1086/496991.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/16206093/pubmed\" target=\"_blank\" id=\"16206093\">16206093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. 2016. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hiemenz JW and Walsh TJ, &ldquo;Lipid Formulations of Amphotericin B: Recent Progress and Future Directions,&rdquo; <i>Clin Infect Dis</i>, 1996, 22(Suppl 2):133-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/8824978/pubmed\" target=\"_blank\" id=\"8824978\">8824978</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kauffman CA, Bustamante B, Chapman SW, et al, &quot;Clinical Practice Guidelines for the Management of Sporotrichosis: 2007 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2007, 45(10):1255-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/17968818/pubmed\" target=\"_blank\" id=\"17968818\">17968818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23083312\"></a>Kauffman CA, Pappas PG, Patterson TF, &ldquo;Fungal Infections Associated With Contaminated Methylprednisolone Injections: Preliminary Report,&rdquo; <i>N Engl J Med</i>, 2012 [epub ahead pf print].<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/23083312/pubmed\" target=\"_blank\" id=\"23083312\">23083312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King CT, Rogers PD, Cleary JD, et al, &quot;Antifungal Therapy During Pregnancy,&quot; <i>Clin Infect Dis</i>, 1998, 27(5):1151-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/9827262/pubmed\" target=\"_blank\" id=\"9827262\">9827262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyman CA and Walsh TJ, &ldquo;Systemically Administered Antifungal Agents. A Review of Their Clinical Pharmacology and Therapeutic Applications,&rdquo; <i>Drugs</i>, 1992, 44(1):9-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/1379913/pubmed\" target=\"_blank\" id=\"1379913\">1379913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mactal-Haaf C, Hoffman M, and Kuchta A, &quot;Use of Anti-infective Agents During Lactation, Part 3: Antivirals, Antifungals, and Urinary Antiseptics,&quot; <i>J Hum Lact</i>, 2001, 17(2):160-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/11847833/pubmed\" target=\"_blank\" id=\"11847833\">11847833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mora-Duarte J, Betts R, Rotstein C, et al, &ldquo;Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis,&rdquo; <i>N Engl J Med</i>, 2002, 347(25):2020-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/12490683/pubmed\" target=\"_blank\" id=\"12490683\">12490683</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pagano L, Offidani M, Fianchi L, et al, &ldquo;Mucormycosis in Hematologic Patients,&rdquo; <i>Haematologica</i>, 2004, 89(2):207-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/15003897/pubmed\" target=\"_blank\" id=\"15003897\">15003897</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-e50. doi: 10.1093/cid/civ933<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span><span class=\"doi\">10.1093/cid/civ933</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel R, &ldquo;Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine,&rdquo; <i>Mayo Clin Proc</i>, 1998, 73(12):1205-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/9868423/pubmed\" target=\"_blank\" id=\"9868423\">9868423</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326. http://cid.oxfordjournals.org/content/early/2016/06/22/cid.ciw326.full.pdf+html. Accessed August 8, 2016.27365388</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perfect JR, Dismukes WE, Dromer F, et al, &quot;Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2010, 50(3):291-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/20047480/pubmed\" target=\"_blank\" id=\"20047480\">20047480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pilmis B, Jullien V, Sobel J, et alLecuit M, Lortholary O, Charlier C. Antifungal drugs during pregnancy: an updated review. <i>J Antimicrob Chemother</i>. 2015;70(1):14-22. doi: 10.1093/jac/dku355<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/25204341/pubmed\" target=\"_blank\" id=\"25204341\">25204341</a>]</span><span class=\"doi\">10.1093/jac/dku355</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rex JH, Bennett JE, and Sugar AM, &ldquo;A Randomized Trial Comparing Fluconazole With Amphotericin B for the Treatment of Candidemia in Patients Without Neutropenia. Candidemia Study Group and the National Institute,&rdquo; <i>N Engl J Med</i>, 1994, 331(20):1325-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/7935701/pubmed\" target=\"_blank\" id=\"7935701\">7935701</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rex JH, Pappas PG, Karchmer AW, et al, &ldquo;A Randomized and Blinded Multicenter Trial of High-Dose Fluconazole Plus Placebo Versus Fluconazole Plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects,&rdquo; <i>Clin Infect Dis</i>, 2003, 36(10):1221-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/12746765/pubmed\" target=\"_blank\" id=\"12746765\">12746765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rex JH, Walsh TJ, Sobel JD, et al, &ldquo;Practice Guidelines for the Treatment of Candidiasis. Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2000, 30(4):662-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/10770728/pubmed\" target=\"_blank\" id=\"10770728\">10770728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ringden O, Andstrom E, Remberger M, et al, &ldquo;Safety of Liposomal Amphotericin B (AmBisome&reg;) in 187 Transplant Recipients Treated With Cyclosporin,&rdquo; <i>Bone Marrow Transplant</i>, 1994, 14(Suppl 5):10-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rokicka M, &ldquo;AmBisome&reg; Treatment of Fungal Sinusitis in Severe Immunocompromised Patient With Acute Lymphoblastic Leukemia Relapsed after Autologous Peripheral Blood Transplantation,&rdquo; <i>ACTA Biomed</i>, 2006, 77(Suppl 2):26-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/16918064/pubmed\" target=\"_blank\" id=\"16918064\">16918064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sacks GS and Cleary JD, &ldquo;Nutritional Impact of Lipid-Associated Amphotericin B Formulations,&rdquo; <i>Ann Pharmacother</i>, 1997, 31(1):121-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/8997484/pubmed\" target=\"_blank\" id=\"8997484\">8997484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Slain D, &ldquo;Lipid-Based Amphotericin B for the Treatment of Fungal Infections,&rdquo; <i>Pharmacotherapy</i>, 1999, 19(3):306-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/10221369/pubmed\" target=\"_blank\" id=\"10221369\">10221369</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/24947530/pubmed\" target=\"_blank\" id=\"24947530\">24947530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed September 29, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walsh TJ, Finberg RW, Arndt C, et al, &ldquo;Liposomal Amphotericin B for Empirical Therapy in Patients With Persistent Fever and Neutropenia,&rdquo; <i>N Engl J Med</i>, 1999, 340(10):764-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/10072411/pubmed\" target=\"_blank\" id=\"10072411\">10072411</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wheat LJ, Freifeld AG, Kleiman MB, et al, &quot;Clinical Practice Guidelines for the Management of Patients With Histoplasmosis: 2007 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2007, 45(7):807-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/liposomal-amphotericin-b-drug-information/abstract-text/17806045/pubmed\" target=\"_blank\" id=\"17806045\">17806045</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9499 Version 149.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24673687\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F134882\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F134901\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F134884\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F134894\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F134885\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F134886\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22902761\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F24673688\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F134852\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F134869\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F134868\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475063\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F134910\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F134859\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F134872\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F134856\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298746\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F134861\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F134863\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6866584\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6866586\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F14637213\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F134865\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F134855\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F134871\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322989\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038526\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9499|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=liposomal-amphotericin-b-patient-drug-information\" class=\"drug drug_patient\">Liposomal amphotericin B: Patient drug information</a></li><li><a href=\"topic.htm?path=liposomal-amphotericin-b-pediatric-drug-information\" class=\"drug drug_pediatric\">Liposomal amphotericin B: Pediatric drug information</a></li></ul></div></div>","javascript":null}